Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
May 8, 2024
May 8, 2024
Suspension of trading of Medincell shares, trading to resume tomorrow
May 8, 2024
May 8, 2024
Medincell enters into strategic co-development and licensing agreement with AbbVie to develop next-generation long-acting injectable therapies
April 16, 2024
April 16, 2024
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria
April 8, 2024
April 8, 2024
MedinCell to present at the 23rd Annual Needham Virtual Healthcare Conference
March 28, 2024
March 28, 2024
Pharmaceutical Industry Veteran Strategist Philippe Guy Becomes Chairman of MedinCell’s Supervisory Board
March 13, 2024
March 13, 2024
Anh Nguyen stepped down from MedinCell Supervisory Board as Member and Chairman Due to Statutory Age Limit
February 19, 2024
February 19, 2024
MedinCell to present at the Evercore ISI 2024 Emerging Biotech Conference
February 15, 2024
February 15, 2024
MedinCell’s partner Teva provides guidance for UZEDY in 2024 and an update on olanzapine LAI (mdc-TJK)
January 31, 2024
January 31, 2024
Teva announces recruitment completion of phase 3 clinical study of mdc-TJK
January 9, 2024
January 9, 2024
Jefferies initiates MedinCell’s coverage with a “Buy” recommendation
January 4, 2024
January 4, 2024
Half-Year results (April 2023 – September 2023)
December 19, 2023
December 19, 2023
Contacts
Medincell
David Heuzé
Head of Corporate and Financial Communications, and ESG
